Zhipeng Xu
- Cancer Research top 1%
- MicroRNA in disease regulation 19
- Cancer-related molecular mechanisms research 14
- Molecular Biology top 5%
- Circular RNAs in diseases 14
- RNA modifications and cancer 11
- Extracellular vesicles in disease 7
-
- Pancreatic function and diabetes 7
- Esophageal Cancer Research and Treatment 4
-
- Ferroptosis and cancer prognosis 4
- Journals
- Nature Communications (1 paper)SHILAP Revista de lepidopterología (2 papers)ACS Nano (1 paper)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Zhipeng Xu
76 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Cancer Research 1.4k
- Molecular Biology 2.0k
- Oncology 213
- Immunology 137
- Epidemiology 214
Countries citing papers authored by Zhipeng Xu
This map shows the geographic impact of Zhipeng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhipeng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhipeng Xu more than expected).
Fields of papers citing papers by Zhipeng Xu
This network shows the impact of papers produced by Zhipeng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhipeng Xu. The network helps show where Zhipeng Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Zhipeng Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 0 | |
| 5 | 2025 | 2 | |
| 6 | 2024 | 0 | |
| 7 | 2024 | 0 | |
| 8 | 2024 | 4 | |
| 9 | 2024 | 0 | |
| 10 | 2023 | 9 | |
| 11 | Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer | 2022 | 3 |
| 12 | [Up-regulated expression of miR-576 inhibits ALK4 expression, regulates JAK/STAT signaling pathway and promotes proliferation and migration of prostatic cancer cells]. | 2022 | 1 |
| 13 | 2022 | 19 | |
| 14 | 2022 | 11 | |
| 15 | 2021 | 3 | |
| 16 | 2020 | 6 | |
| 17 | 2019 | 48 | |
| 18 | 2019 | 39 | |
| 19 | 2016 | 98 | |
| 20 | 2015 | 28 |
About Zhipeng Xu
Zhipeng Xu is a scholar working on Cancer Research, Molecular Biology and Geriatrics and Gerontology, having authored 89 papers that have together received 2.7k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (19 papers), Cancer-related molecular mechanisms research (14 papers), Circular RNAs in diseases (14 papers), RNA modifications and cancer (11 papers), Extracellular vesicles in disease (7 papers), Pancreatic function and diabetes (7 papers), Ferroptosis and cancer prognosis (4 papers) and Esophageal Cancer Research and Treatment (4 papers). The work is most often cited by research in Cancer Research (1.4k citations), Molecular Biology (2.0k citations) and Oncology (213 citations). Zhipeng Xu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Lutao Du, Ruiming Wang, Peilong Li, Taiyi Zhang, Xiaowen Huang, Zekuan Xu, Bowen Li, Zhongyuan He, Xiaoxu Huang and Jingjing Zhang. Their work appears in journals such as Nature Communications, SHILAP Revista de lepidopterología and ACS Nano.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.